These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

356 related articles for article (PubMed ID: 26768633)

  • 1. The Distribution of Liver Steatosis, Fibrosis, Steatohepatitis and Inflammation Activity in Alcoholics According to FibroMax Test.
    Gudowska M; Wojtowicz E; Cylwik B; Gruszewska E; Chrostek L
    Adv Clin Exp Med; 2015; 24(5):823-7. PubMed ID: 26768633
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Noninvasive biomarkers for the screening of fibrosis, steatosis and steatohepatitis in patients with metabolic risk factors: FibroTest-FibroMax experience.
    Munteanu M; Ratziu V; Morra R; Messous D; Imbert-Bismut F; Poynard T
    J Gastrointestin Liver Dis; 2008 Jun; 17(2):187-91. PubMed ID: 18568141
    [No Abstract]   [Full Text] [Related]  

  • 3. The Higher Prevalence of Non-Alcoholic versus Alcoholic Steatohepatitis in Alcoholics.
    Gruszewska E; Gudowska M; Wojtowicz E; Cylwik B; Szmitkowski M; Chrostek L
    Clin Lab; 2015; 61(11):1769-74. PubMed ID: 26732004
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The diagnostic value of non-invasive biochemical biomarkers in alcohol abuse].
    Supronowicz Ł; Wójtowicz E; Cylwik B; Gruszewska E; Chrostek L
    Pol Merkur Lekarski; 2013 Sep; 35(207):148-50. PubMed ID: 24224451
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Performance of biomarkers FibroTest, ActiTest, SteatoTest, and NashTest in patients with severe obesity: meta analysis of individual patient data.
    Poynard T; Lassailly G; Diaz E; Clement K; Caïazzo R; Tordjman J; Munteanu M; Perazzo H; Demol B; Callafe R; Pattou F; Charlotte F; Bedossa P; Mathurin P; Ratziu V;
    PLoS One; 2012; 7(3):e30325. PubMed ID: 22431959
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Performance of the SteatoTest, ActiTest, NashTest and FibroTest in a multiethnic cohort of patients with type 2 diabetes mellitus.
    Bril F; McPhaul MJ; Caulfield MP; Castille JM; Poynard T; Soldevila-Pico C; Clark VC; Firpi-Morell RJ; Lai J; Cusi K
    J Investig Med; 2019 Feb; 67(2):303-311. PubMed ID: 30309884
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FibroMAX: towards a new universal biomarker of liver disease?
    Morra R; Munteanu M; Imbert-Bismut F; Messous D; Ratziu V; Poynard T
    Expert Rev Mol Diagn; 2007 Sep; 7(5):481-90. PubMed ID: 17892356
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Validation of noninvasive biomarkers (FibroTest, SteatoTest, and NashTest) for prediction of liver injury in patients with morbid obesity.
    Lassailly G; Caiazzo R; Hollebecque A; Buob D; Leteurtre E; Arnalsteen L; Louvet A; Pigeyre M; Raverdy V; Verkindt H; Six MF; Eberle C; Patrice A; Dharancy S; Romon M; Pattou F; Mathurin P
    Eur J Gastroenterol Hepatol; 2011 Jun; 23(6):499-506. PubMed ID: 21499110
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Steatosis and non-alcoholic steatohepatitis in patients with chronic hepatitis due to hepatitis C virus infection].
    Coral G; de Mattos AA; de Mattos AZ; dos Santos DE
    Arq Gastroenterol; 2006; 43(4):265-8. PubMed ID: 17406752
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Non alcoholic steatohepatitis].
    Manero E; Findor JA; Avagnina A; de Elizalde S; Elsner B
    Medicina (B Aires); 1994; 54(6):625-9. PubMed ID: 7658998
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum ferritin is a discriminant marker for both fibrosis and inflammation in histologically proven non-alcoholic fatty liver disease patients.
    Manousou P; Kalambokis G; Grillo F; Watkins J; Xirouchakis E; Pleguezuelo M; Leandro G; Arvaniti V; Germani G; Patch D; Calvaruso V; Mikhailidis DP; Dhillon AP; Burroughs AK
    Liver Int; 2011 May; 31(5):730-9. PubMed ID: 21457446
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The diagnostic value of combining carbohydrate-deficient transferrin, fibrosis, and steatosis biomarkers for the prediction of excessive alcohol consumption.
    Imbert-Bismut F; Naveau S; Morra R; Munteanu M; Ratziu V; Abella A; Messous D; Thabut D; Benhamou Y; Poynard T
    Eur J Gastroenterol Hepatol; 2009 Jan; 21(1):18-27. PubMed ID: 19011575
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolic syndrome is associated with severe fibrosis in chronic viral hepatitis and non-alcoholic steatohepatitis.
    Tsochatzis E; Papatheodoridis GV; Manesis EK; Kafiri G; Tiniakos DG; Archimandritis AJ
    Aliment Pharmacol Ther; 2008 Jan; 27(1):80-9. PubMed ID: 17919273
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reliability of transient elastography for the detection of fibrosis in non-alcoholic fatty liver disease and chronic viral hepatitis.
    Gaia S; Carenzi S; Barilli AL; Bugianesi E; Smedile A; Brunello F; Marzano A; Rizzetto M
    J Hepatol; 2011 Jan; 54(1):64-71. PubMed ID: 20932598
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictive value of ALT levels for non-alcoholic steatohepatitis (NASH) and advanced fibrosis in non-alcoholic fatty liver disease (NAFLD).
    Verma S; Jensen D; Hart J; Mohanty SR
    Liver Int; 2013 Oct; 33(9):1398-405. PubMed ID: 23763360
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Nonalcoholic fatty liver hepatitis and fatty cirrhosis mimicking alcoholic liver diseases].
    Spech HJ; Liehr H; Mitschke H
    Z Gastroenterol; 1983 Nov; 21(11):651-9. PubMed ID: 6659631
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Unconjugated bilirubin, a potent endogenous antioxidant, is decreased in patients with non-alcoholic steatohepatitis and advanced fibrosis.
    Salomone F; Li Volti G; Rosso C; Grosso G; Bugianesi E
    J Gastroenterol Hepatol; 2013 Jul; 28(7):1202-8. PubMed ID: 23425054
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cryoglobulinemia is associated with steatosis and fibrosis in chronic hepatitis C.
    Saadoun D; Asselah T; Resche-Rigon M; Charlotte F; Bedossa P; Valla D; Piette JC; Marcellin P; Cacoub P
    Hepatology; 2006 Jun; 43(6):1337-45. PubMed ID: 16729318
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of asymptomatic liver fibrosis in alcoholic patients using fibroscan: prospective comparison with seven non-invasive laboratory tests.
    Nguyen-Khac E; Chatelain D; Tramier B; Decrombecque C; Robert B; Joly JP; Brevet M; Grignon P; Lion S; Le Page L; Dupas JL
    Aliment Pharmacol Ther; 2008 Nov; 28(10):1188-98. PubMed ID: 18705692
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fibromax and inflamatory markers cannot replace liver biopsy in the evaluation of non-alcoholic fatty liver disease.
    Lardi LL; Lul RM; Port GZ; Coral GP; Peres A; Dornelles GP; Branco F; Fernandes S; Leães CG; Mattos AA; Buss C; Tovo CV
    Minerva Gastroenterol (Torino); 2022 Mar; 68(1):85-90. PubMed ID: 32700499
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.